Literature DB >> 32299015

Aspirin-exacerbated respiratory disease.

Hannah Wangberg1, Andrew A White2.   

Abstract

Aspirin-exacerbated respiratory disease (AERD) classically presents with severe asthma, nasal polyposis, and respiratory exacerbations in response to cyclooxygenase (COX)-1 inhibition. Recent advances in our understanding of AERD have revealed multiple facets of immune dysregulation, including diminished prostaglandin E2 (PGE2) function and elevated levels of both cysteinyl leukotrienes (CysLTs) and innate cytokines such as interleukin 33 (IL-33). Inflammatory mediators in AERD heighten the recruitment and activation of innate lymphoid cells type 2 (ILC2), mast cells, eosinophils, and platelet-adherent leukocytes. This contributes to a cyclical pattern of type 2 inflammation. Here, we highlight current understanding of the immunopathogenesis of AERD.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32299015     DOI: 10.1016/j.coi.2020.02.006

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  3 in total

Review 1.  Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.

Authors:  Lucyna Mastalerz; Katarzyna E Tyrak
Journal:  Clin Transl Allergy       Date:  2021-08-13       Impact factor: 5.871

Review 2.  Cellular interactions in aspirin-exacerbated respiratory disease.

Authors:  Jana H Badrani; Taylor A Doherty
Journal:  Curr Opin Allergy Clin Immunol       Date:  2021-02-01

3.  Computational analysis of eugenol inhibitory activity in lipoxygenase and cyclooxygenase pathways.

Authors:  Francisco das Chagas Pereira de Andrade; Anderson Nogueira Mendes
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.